[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3319956T3 - Substituerede oxopyridinderivater - Google Patents

Substituerede oxopyridinderivater Download PDF

Info

Publication number
DK3319956T3
DK3319956T3 DK16734672.5T DK16734672T DK3319956T3 DK 3319956 T3 DK3319956 T3 DK 3319956T3 DK 16734672 T DK16734672 T DK 16734672T DK 3319956 T3 DK3319956 T3 DK 3319956T3
Authority
DK
Denmark
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
oxopyridine
Prior art date
Application number
DK16734672.5T
Other languages
English (en)
Inventor
Jens Ackerstaff
Susanne Röhrig
Alexander Hillisch
Katharina Meier
Stefan Heitmeier
Adrian Tersteegen
Jan Stampfuss
Daniel Meibom
Dieter Lang
Pascal Ellerbrock
Nunez Eloisa Jimenez
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK3319956T3 publication Critical patent/DK3319956T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK16734672.5T 2015-07-09 2016-07-05 Substituerede oxopyridinderivater DK3319956T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
DK3319956T3 true DK3319956T3 (da) 2021-03-29

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16734672.5T DK3319956T3 (da) 2015-07-09 2016-07-05 Substituerede oxopyridinderivater

Country Status (40)

Country Link
US (3) US10421742B2 (da)
EP (1) EP3319956B1 (da)
JP (1) JP6871180B2 (da)
KR (1) KR102596164B1 (da)
CN (2) CN113292539B (da)
AU (1) AU2016289746B2 (da)
CA (1) CA2990901A1 (da)
CL (1) CL2018000039A1 (da)
CO (1) CO2018000113A2 (da)
CR (1) CR20180017A (da)
CU (1) CU24512B1 (da)
CY (1) CY1123996T1 (da)
DK (1) DK3319956T3 (da)
DO (1) DOP2018000004A (da)
EA (1) EA036208B1 (da)
EC (1) ECSP18001308A (da)
ES (1) ES2856554T3 (da)
GE (1) GEP20197046B (da)
HK (1) HK1255045A1 (da)
HR (1) HRP20210459T1 (da)
HU (1) HUE053552T2 (da)
IL (1) IL256556B (da)
JO (1) JO3703B1 (da)
LT (1) LT3319956T (da)
MA (1) MA42376B1 (da)
MX (1) MX2018000076A (da)
MY (1) MY196640A (da)
NI (1) NI201800001A (da)
PE (1) PE20180538A1 (da)
PH (1) PH12018500057A1 (da)
PL (1) PL3319956T3 (da)
RS (1) RS61584B1 (da)
SI (1) SI3319956T1 (da)
SV (1) SV2018005610A (da)
TN (1) TN2018000011A1 (da)
TW (1) TWI717367B (da)
UA (1) UA122341C2 (da)
UY (1) UY36780A (da)
WO (1) WO2017005725A1 (da)
ZA (1) ZA201800826B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046158A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN107428689A (zh) * 2015-03-19 2017-12-01 拜耳制药股份公司 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10633375B2 (en) 2016-08-31 2020-04-28 Jinagsu Hengrui Medicine Co., Ltd Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
LT3765452T (lt) * 2018-03-15 2022-05-25 Bayer Aktiengesellschaft Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas
KR20200141445A (ko) 2018-04-10 2020-12-18 바이엘 파마 악티엔게젤샤프트 치환된 옥소피리딘 유도체
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL FORMS OF AN OXOPICOLINAMIDE DERIVATIVE AND MANUFACTURING PROCESS FOR IT
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
EP3898611A1 (en) * 2018-12-17 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
AR117435A1 (es) 2018-12-21 2021-08-04 Bayer Ag Derivados de oxopiridina sustituidos
WO2020127508A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN114206854B (zh) * 2019-09-27 2023-02-24 深圳信立泰药业股份有限公司 FXIa抑制剂及其制备方法和医药用途
WO2022057849A1 (zh) 2020-09-17 2022-03-24 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
AU2022232704A1 (en) 2021-03-09 2023-08-31 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
BR112023016298A2 (pt) 2021-03-09 2023-10-03 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262734A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303A (zh) * 2022-12-21 2023-05-09 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736A (zh) * 2022-12-26 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
WO2024200335A1 (en) 2023-03-31 2024-10-03 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32 h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN116621742A (zh) * 2023-06-09 2023-08-22 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1526131A1 (en) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
NZ572418A (en) 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
NO2794597T3 (da) * 2011-12-21 2018-04-14
DK2880026T3 (da) * 2012-08-03 2017-06-06 Bristol Myers Squibb Co Dihydropyridon-p1 som faktor xia-hæmmere
EP2968207A4 (en) 2013-03-14 2016-09-28 Chdi Foundation Inc HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6410819B2 (ja) 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用
EP3063150B1 (de) 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
KR102413453B1 (ko) 2014-01-31 2022-06-28 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
WO2015120777A1 (zh) * 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046158A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10167280B2 (en) 2014-09-24 2019-01-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10071995B2 (en) * 2014-09-24 2018-09-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CA2961981A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046157A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3331872B1 (en) * 2015-08-05 2019-09-25 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors

Also Published As

Publication number Publication date
SV2018005610A (es) 2018-04-27
KR20180026761A (ko) 2018-03-13
JP2018519323A (ja) 2018-07-19
MA42376B1 (fr) 2021-04-30
RS61584B1 (sr) 2021-04-29
JO3703B1 (ar) 2021-01-31
IL256556A (en) 2018-02-28
US10421742B2 (en) 2019-09-24
US20230024752A1 (en) 2023-01-26
CR20180017A (es) 2018-03-07
TWI717367B (zh) 2021-02-01
PL3319956T3 (pl) 2021-07-05
JP6871180B2 (ja) 2021-05-12
MY196640A (en) 2023-04-25
HRP20210459T1 (hr) 2021-05-14
KR102596164B1 (ko) 2023-11-01
ECSP18001308A (es) 2018-03-31
CU20180001A7 (es) 2018-06-05
CU24512B1 (es) 2021-05-12
CN113292539B (zh) 2023-12-22
PE20180538A1 (es) 2018-03-20
NI201800001A (es) 2018-10-19
SI3319956T1 (sl) 2021-02-26
TN2018000011A1 (en) 2019-07-08
CN108026072A (zh) 2018-05-11
US20180194745A1 (en) 2018-07-12
EA036208B1 (ru) 2020-10-14
UY36780A (es) 2017-01-31
CO2018000113A2 (es) 2018-06-12
TW201706261A (zh) 2017-02-16
WO2017005725A1 (en) 2017-01-12
CL2018000039A1 (es) 2018-07-13
AU2016289746A1 (en) 2018-01-25
CN108026072B (zh) 2021-08-17
GEP20197046B (en) 2019-12-10
CY1123996T1 (el) 2022-07-22
US11180471B2 (en) 2021-11-23
HUE053552T2 (hu) 2021-07-28
DOP2018000004A (es) 2018-01-31
CA2990901A1 (en) 2017-01-12
LT3319956T (lt) 2021-02-10
EA201890111A1 (ru) 2018-06-29
EP3319956A1 (en) 2018-05-16
US20190367478A1 (en) 2019-12-05
ZA201800826B (en) 2021-08-25
MA42376A (fr) 2018-05-16
BR112018000209A2 (pt) 2018-09-04
AU2016289746B2 (en) 2020-08-20
MX2018000076A (es) 2018-02-26
EP3319956B1 (en) 2021-01-06
ES2856554T3 (es) 2021-09-27
UA122341C2 (uk) 2020-10-26
IL256556B (en) 2021-02-28
PH12018500057A1 (en) 2018-07-09
CN113292539A (zh) 2021-08-24
HK1255045A1 (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331528T3 (da) Muskarinagonister
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
DK3231803T3 (da) Dihydroindolizinonderivat
DK3270930T3 (da) Præeklampsi
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
DK3394281T3 (da) Gærcelle
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
DK3645513T3 (da) Benzazepinderivater
DK3274482T3 (da) Stenborsknop
DK3318308T3 (da) Badmintonketsjer
DE112015005906A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
DE112016001124A5 (de) Spannschutz
DE102015000551A8 (de) Rotationszerstäuberturbine